ALS Center Tours

CHU Bretonneau

The ALS Center Tours is dedicated to delivering high quality patient care and are involved in numerous research projects.

logo tourss
CHU Bretonneau

Our multidisciplinary team aims to provide care and support for patients and their families. Patients are routinely (every three months) seen by specialists in our team. Together with the NeuroCenter Network we coordinate medical, paramedical and social support at home for patients. We also take part in various research activities. These are directed to identify ALS risk genes, new biomarkers for diagnosis and prognosis, and clinical studies to develop suitable treatments. Finally, we are setting up an ALS Registry in the Center Val de Loire.

Contact
Location
CHU Bretonneau 2 Boulevard Tonnellé, 37044 Tours

Our Specialists

Philippe Corcia

Professor of Neurology

Philippe Corcia is Professor of Neurology and responsible for the ALS Center […]

Philippe Corcia
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more